Decreased expression of ALDH1L1 is associated with a poor prognosis in hepatocellular carcinoma

Medical Oncology

Volumn 29, Issue 3, 2012, Pages 1843-1849

  Chen, Xiao Qian ^a   He, Juan Ru ^b   Wang, Hui Yun ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b GUANGXI MEDICAL UNIVERSITY   (China)

Author keywords

ALDH1L1; Folate; Hepatocellular carcinoma; Prognosis

Indexed keywords

ALDEHYDE DEHYDROGENASE; ALDEHYDE DEHYDROGENASE 1 FAMILY MEMBER L1; ALPHA FETOPROTEIN; HEPATITIS B SURFACE ANTIGEN; MESSENGER RNA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURGERY; CANCER TISSUE; CLINICAL FEATURE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER; LIVER CELL CARCINOMA; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL PREDICTION; TISSUE LEVEL; TUMOR DIFFERENTIATION; WESTERN BLOTTING;

ADULT; ALDEHYDE DEHYDROGENASE; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM GRADING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 84872782278     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-011-0075-x     Document Type: Article

References (25)

1. Bruix J, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European association for the study of the liver. J Hepatol. 2001;35(3): 421-30.
2. He J, et al. Major causes of death among men and women in China. N Engl J Med. 2005;353(11):1124-34.
3. Seeff LB, Hoofnagle JH. Epidemiology of hepatocellular carcinoma in areas of low hepatitis B and hepatitis C endemicity. Oncogene. 2006;25(27):3771-7.
4. Feo F, et al. Hepatocellular carcinoma as a complex polygenic disease. Interpretive analysis of recent developments on genetic predisposition. Biochim Biophys Acta. 2006;1765(2):126-47.
5. Kwon OS, et al. Effect of alcohol on the development of hepatocellular carcinoma in patients with hepatitis B virus-related cirrhosis: a cross-sectional case-control study. Korean J Hepatol. 2010;16(3):308-14.
6. Chen Ban K, et al. Comparison of the expression of beta-catenin in hepatocellular carcinoma in areas with high and low levels of exposure to aflatoxin B1. J Surg Oncol. 2004;86(3):157-63.
7. Bosch FX, Ribes J, Borras J. Epidemiology of primary liver cancer. Semin Liver Dis. 1999;19(3):271-85.
8. Krupenko SA. FDH: an aldehyde dehydrogenase fusion enzyme in folate metabolism. Chem Biol Interact. 2009;178(1-3):84-93.
9. Krupenko SA, Oleinik NV. 10-formyltetrahydrofolate dehydrogenase one of the major folate enzymes, is down-regulated in tumor tissues and possesses suppressor effects on cancer cells. Cell Growth Differ. 2002;13(5):227-36.
10. Krebs HA, Hems R, Tyler B. The regulation of folate and methionine metabolism. Biochem J. 1976;158(2):341-53.
11. Kim DW, et al. Properties of tetrahydropteroylpentaglutamate bound to 10-formyltetrahydrofolate dehydrogenase. Biochemistry. 1996;35(49):15772-83.
12. Wagner C, et al. 10-Formyltetrahydrofolate dehydrogenase: identification of the natural folate ligand, covalent labeling, and partial tryptic digestion. Arch Biochem Biophys. 1995;316(1):141-7.
13. Oleinik NV, Krupenko SA. Ectopic expression of 10-formyltetrahydrofolate dehydrogenase in A549 cells induces G1 cell cycle arrest and apoptosis. Mol Cancer Res. 2003;1(8):577-88.
14. Oleinik NV, Krupenko NI, Krupenko SA. ALDH1L1 inhibits cell motility via dephosphorylation of cofilin by PP1 and PP2A. Oncogene. 2010;29(47):6233-44.
15. Tackels-Horne D, et al. Identification of differentially expressed genes in hepatocellular carcinoma and metastatic liver tumors by oligonucleotide expression profiling. Cancer. 2001;92(2):395-405.
16. Schmittgen TD, Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008;3(6):1101-8.
17. Bailey LB, Gregory JF 3rd. Folate metabolism and requirements. J Nutr. 1999;129(4):779-82.
18. Benkovic SJ. The transformylase enzymes in de novo purine biosynthesis. Trends Biochem Sci. 1984;9:320-2.
19. Jhaveri MS, Wagner C, Trepel JB. Impact of extracellular folate levels on global gene expression. Mol Pharmacol. 2001;60(6): 1288-95.
20. Kruman II, et al. Folic acid deficiency and homocysteine impair DNA repair in hippocampal neurons and sensitize them to amyloid toxicity in experimental models of Alzheimer's disease. J Neurosci. 2002;22(5):1752-62.
21. Huang RF, et al. Folate deficiency induces a cell cycle-specific apoptosis in HepG2 cells. J Nutr. 1999;129(1):25-31.
22. Rodriguez FJ, et al. Gene expression profiling of NF-1-associated and sporadic pilocytic astrocytoma identifies aldehyde dehydrogenase 1 family member L1 (ALDH1L1) as an underexpressed candidate biomarker in aggressive subtypes. J Neuropathol Exp Neurol. 2008;67(12):1194-204.
23. Oleinik NV, et al. Cancer cells activate p53 in response to 10-formyltetrahydrofolate dehydrogenase expression. Biochem J. 2005;391(Pt 3):503-11.
24. Oleinik NV, Krupenko NI, Krupenko SA. Cooperation between JNK1 and JNK2 in activation of p53 apoptotic pathway. Oncogene. 2007;26(51):7222-30.
25. Ghose S, et al. 10-formyltetrahydrofolate dehydrogenase-induced c-Jun-NH2-kinase pathways diverge at the c-Jun-NH2-kinase substrate level in cells with different p53 status. Mol Cancer Res. 2009;7(1):99-107.